The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister Mette Frederiksen to discuss preparations for a ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...
AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...
Korea Joongang Daily on MSN11h
Hanmi seeks to gain on Wegovy with its own weight-loss drugHanmi Pharmaceutical Senior Vice President Choi In-young, head of the R&D center, speaks to Korean media outlets at a press ...
The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.
Investor's Business Daily on MSN18h
After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
The podcast features Numerator Chief Economist Leo Feler, who talks about the potential impact of GLP-1 drugs like Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback